RAPID COMMUNICATIONS Use of Alerntuzumab and Tacrolirnus Monotherapy for Cadaveric Liver Transplantation: With Particular Reference to Hepatitis C Virus

We have proposed that the mechanisms of alloengraftment and variable acquired tolerance can be facilitated by minimum posttransplant immunosuppression. It was further suggested that the efficacy of minimalistic treatment could be enhanced by preoperative recipient conditioning with an antilymphoid antibody preparation. A total of 76 adults (38 hepatitis C virus [HCY]-, 38 HCY+) were infused with 30 mg alemtuzumab before primary cadaveric liver transplantation and maintained afterward on daily monotherapy unless breakthrough rejection mandated additional agents. In stable patients, the intervals between tacrolimus doses were lengthened ("spaced weaning") after approximately 4 months. Eighty-four contemporaneous_nonlymphoid-depleted liver recipients (58 HCY-, 26 HCY+) were treated with conventional postoperative im~unosuppression. The overall incidence of rejection was similar with the two strategies of immunosuppression. With follow-ups of 14 to 22 months, patient and primary graft survival in HCYcases are 97% and 90%, respectively, with alemtuzumab depletion plus minimal immunosuppression versus 71 % and 70%, respectively, under conventional immunosuppression. In HCY+ recipients, current patient and graft survival in the alemtuzumab-pretreated group are 71 % and 70% versus 65% and 54%, respectively, under conventional treatment. With both strategies of immunosuppression, the adverse effect of preexisting HCY on survival parameters and graft function already was significant at the I-year milestone, but its extent was not evident until the second year. With or without HCY, 62% of the 64 surviving lymphoid-depleted patients are on spaced immunosuppression, and four patients receive no immunosuppression. Lymphoid depletion with alemtuzumab and minimalistic maintenance immunosuppression is a practical strategy of liver transplantation in HCYrecipients but not HCY+ recipients.